Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    

| More

Dr Lal Pathlabs - Multiple growth levers - ICICI Securities

Posted On: 2020-08-03 08:43:19

Dr Lal Pathlabs' (Dr Lal) Q1FY21 performance was above estimate even in challenging environment, aided by COVID-19 tests and successful cost control initiatives. COVID-19 tests contributed ~21% to sales and other revenue declined 37.3% YoY, as expected. Overall, revenue declined 20.6%, EBITDA margin was down 1,020bps to 18.2% and adj PAT was down 51.7% to Rs284mn. The business has recovered to ~90% of pre-COVID levels and we expect healthy growth in coming months. We believe Dr Lal would benefit the most with multiple growth levers such as faster shift of unorganized business to organized players in current scenario, potential consolidation in industry via inorganic or partnership route (Dr Lal has cash balance of over Rs7bn as on Mar'20) and upside from COVID-19 related RT-PCR & anti-body tests. Upgrade to BUY from Add.

- Expect positive revenue growth from Q2FY21: Dr Lal was impacted significantly in Q1FY21 due to lockdown across the country. However, COVID-19 tests helped in arresting revenue decline to 20.6% against estimated decline of 37.6%. COVID-19 tests contributed ~21% to revenue and we expect it to drop in ensuing quarters. The volumes in regular (ex-COVID) business has recovered to ~90% of pre-COVID levels and we estimate flattish volumes YoY in Q2FY21. The volume decline in ex-COVID business was 32.6% in number of patients and realisation dropped 7% as samples per patient fell. We believe business would improve materially with easing of lockdown in coming quarters and estimate flat volumes in FY21E.

- Cost control initiatives supported margin: Dr Lal reported an EBITDA margin of 18.2% (-1,020bps YoY) against estimated 1.0%. Reduction of 20.9% YoY in S,G&A costs was a key factor in supporting margin. This reduction was driven by negotiating new rentals, reducing promotions etc. Revenue from COVID-19 related tests also helped in absorbing fixed costs. We expect EBITDA margin to improve hereon with pick-up in patient volumes and estimate 90bps drop in EBITDA margin in FY21E.

- Outlook: We expect Dr Lal to outperform industry growth and register revenue, EBITDA and PAT growth at CAGRs of 15.3%, 20.9% and 26.8%, respectively, over FY20-FY22E. RoE and RoCE would remain strong at 27.3% and 25.9%, respectively, in FY22E whereas RoIC would move to 93.0%. We are positive on the long-term outlook considering the company's strong brand franchise with sustainable growth, expansion potential, healthy FCFF generation and strong return ratios.

- Valuation: We raise FY21-22 revenue/EPS estimates by 6-7/8-12% to factor in revenue from COVID-19 tests, early recovery in volumes and better margin as seen in Q1FY21. We upgrade Dr Lal to BUY from Add with a revised DCF-based target price of Rs2,176/share (earlier: Rs1,710/share) implying 50.0xFY22E EPS and 33.6xFY22E EV/EBITDA. Key downside risks: Higher-than-expected competition, pricing pressures and prolonged impact of COVID-19.

Shares of Dr. Lal PathLabs Ltd was last trading in BSE at Rs.1862.45 as compared to the previous close of Rs. 1888.85. The total number of shares traded during the day was 7805 in over 1058 trades.

The stock hit an intraday high of Rs. 1908.15 and intraday low of 1821.4. The net turnover during the day was Rs. 14596248.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:


Mutual Fund Review - September, 2020 - ICICI Securities

UTI AMC announces IPO date - Angel Broking

Asian Paints - Mr. Amarjeet Maurya - AVP - Mid Caps, Angel Broking Ltd

Britannia Industries - Mr. Amarjeet Maurya - AVP - Mid Caps, Angel Broking Ltd

Hexaware Technologies (Not Rated): Hexaware accepts 475/share as final delisting price - ICICI Securities

CAMS IPO - Day 2 Subscription - Angel Boking

Chemcon Speciality Chemicals - IPO subscribed 12.62 times on second day - Angel Broking

General insurance - Fire, health remain growth drivers, rising Covid claims a concern - ICICI Securities

Supreme Industries - Perfect recipe for rerating; upgrade to BUY - ICICI Securities

Titan Company - Best positioned to gain from faster-than-expected recovery. Upgrade to ADD - ICICI Securities

Sector Update - Telecom - Sep 23, 2020 - ICICI Securities

Allcargo Logistics - Highlights of Blackstone deal - ICICI Securities

I-direct Instinct - Gokaldas Exports

Economy: RBI's trilemma: allows for INR strength - Kotak

HCL Technologies - Company Update - ICICI Securities

Chemcon Speciality Chemicals - IPO Review - ICICI Securities

Angel Broking - IPO Note - YES Securities

TCS - Announcement of its blockhchain based solutions on Microsoft Azure - Angel Broking

Amber Enterpirses acquire Sidwal - Angel Broking

Dixon Technologies - Buy - YES Securities

HCL Technologies acquisition of DWS Limited - Angel Broking

Allcargo Logistics CFO Resignation - Angel Broking

Upgrade to BUY on Gateway Distriparks - Strengthening the balance sheet - HDFC Securities

BUY on ITD Cementation - Execution pickup awaited - HDFC Securities

Allcargo Logistics - Trying to stich through an integrated offering - ICICI Securities

Polymer price tracker - Other polymer (ex-PVC) prices too firm up - ICICI Securities

Angel Broking - IPO Review - ICICI Securities

IPO Review - Computer Age Management Services - ICICI Securities

Company Update - EIH Ltd - ICICI Securities

Gladiator Stocks - Godrej Properties - ICICI Securities

Company Update - Dr Reddy's Laboratories - ICICI Securities

Gladiator Stocks: Pharma Thematic - ICICI Securities

Company Update - Housing & Urban Development - ICICI Securities

Covid Recovery Pulse - E-Way bill generation shows recovery signs with auto volumes flat - ICICI Securities

Quant Pick - UltraTech Cement - ICICI Securities

Lupin & Cipla - Positive News - Angel Broking

Sterling and Wilson Solar Ltd - 106.71 MW order win - Angel Broking

Dr. Reddy's Laboratories - Settles Revlimid litigation in US - ICICI Securities

Natco Pharma - Natco to launch first generic Revlimid - ICICI Securities

Solar Industries - Overseas and defence key to profitability - ICICI Securities

Federal Bank - Strengthening liability muscle; fees & charges revised upwards - ICICI Securities

HCL Technologies Mr. Jyoti Roy, DVP - Equity Strategist, Angel Broking Ltd


I-direct Instinct - Intellect Design Arena

P&G Health - Company Update - ICICI Securities

Relaxo Footwears - Mr. Amarjeet Maurya- AVP - Mid Caps, Angel Broking Ltd

Bata India - Mr. Amarjeet Maurya- AVP - Mid Caps, Angel Broking Ltd

Listing of Happiest Minds Technologies - Angel Broking

Dr. Reddy's Lab - Sep 17, 2020 - Angel Broking

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019